|Mr. Christopher A. Bunka||Chairman & CEO||223.28k||N/A||1962|
|Mr. John M. Docherty||Pres & Director||195.74k||N/A||1969|
|Mr. Allan Spissinger C.A., CPA||CFO, Corp. Sec. & Treasurer||112.38k||N/A||1969|
|Vanessa Carle||Head of Legal||N/A||N/A||N/A|
|Dr. Philip Ainslie||Advisor & Consultant||N/A||N/A||N/A|
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology that changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing, and higher effectiveness for lipophilic active molecules. DehydraTECH enhances bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine, and other molecules. The company has licensed DehydraTECH to various companies in the cannabis industry for use in cannabinoid beverages, edibles, and oral products, as well as to tobacco producers for the development of smokeless oral-based nicotine products. It is also involved in the production of enhanced oral products under the ViPova, Lexaria Energy, TurboCBD, and ChrgD+ brands. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.